SK Biopharmaceuticals
SK Biopharmaceuticals is a global pioneer in the development of new drugs
SK Biopharmaceuticals is a global pioneer in the development of new drugs
SK Biopharmaceuticals is a global pioneer in the development of new drugs and is a part of the global conglomerate SK Group, the second largest company in Korea. Responsible for developing innovative next-generation drugs within the SK Group, the company has been focusing on new drug candidates in the area of CNS (Central Nervous System), led by the clinical development center (SK Life Science) in the United States and the research center in Pangyo Techno-valley, Gyeonggi-do.
With its experience and expertise in the CNS area, SK Biopharmaceuticals aims to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, the company envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing.
Founded in 2011, SK Biopharmaceuticals operates in the Biotechnology and Manufacturing industries. The latest investment of Grant investment was received on 14 November 2022 from the Korea Drug Development Fund.
For more information, visit their website at www.skbp.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | 1 | Korea Drug Development Fund | 14 Nov 2022 |
| Series A | $180.00M | 5 |
|
26 Nov 2021 |
| Seed Round | Unknown | 1 | Korea Drug Development Fund | 03 Mar 2012 |
No recent news or press coverage available for SK Biopharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
